Written Exposure Therapy + Ketamine for Post-Traumatic Stress Disorder
Trial Summary
What is the purpose of this trial?
This trial combines writing therapy and ketamine injections to help people with chronic PTSD who don't fully benefit from current treatments. Ketamine makes the brain more adaptable, and writing about trauma helps reduce its emotional impact. Ketamine has shown benefits for treating PTSD symptoms and is being explored in combination with psychotherapy for lasting effects.
Will I have to stop taking my current medications?
You may need to stop taking certain medications like opioid medications or daytime benzodiazepines two weeks before the study starts. However, you can continue other psychotropic medications if the dose has been stable for at least three months.
What data supports the effectiveness of the drug Ketamine for treating Post-Traumatic Stress Disorder?
Research shows that ketamine can rapidly reduce PTSD symptoms, especially in civilian populations, and has been effective in decreasing depression and anxiety when combined with psychotherapy. However, its effectiveness in military populations is less clear, and further studies are needed to explore its benefits.12345
What makes the treatment of Written Exposure Therapy + Ketamine unique for PTSD?
This treatment combines Written Exposure Therapy, which is a brief and efficient form of exposure therapy, with ketamine, a drug known for its rapid action and novel mechanism in treating mental health conditions, offering a potentially faster and more effective approach for PTSD compared to traditional treatments.25678
Research Team
Oneysha Brown, BA
Principal Investigator
Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai
Adriana Feder, MD
Principal Investigator
Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a total of six ketamine infusions and participate in five sessions of Written Exposure Therapy (WET)
Follow-up
Participants are monitored for safety and effectiveness after treatment, with weekly assessments until 12 weeks following the start of WET
Extended Follow-up
Participants who remain improved are assessed monthly for up to 24 weeks
Treatment Details
Interventions
- Ketamine
- Written Exposure Therapy
Ketamine is already approved in United States, European Union, Canada for the following indications:
- Anesthesia
- Treatment-resistant depression
- Anesthesia
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor